President and Interim Chief Executive Officer
Richard Bagley joined Samus Therapeutics in November 2016. Most recently, Mr. Bagley served as President, Chief Operating Officer and Chief Financial Officer of ZIOPHARM Oncology. Mr. Bagley began his 45 plus year career in industry at SmithKline in product management. He was later named President of E.R. Squibb U.S. before switching to the biotechnology industry, serving in Chief Executive roles at ImmuLogic, ProSript and AltaRex and as President/COO/CFO of ZIOPHARM. In these roles, Mr. Bagley completed six major biotech-partnering transactions and raised over $500 million from corporate partnering arrangements and equity offerings. Among his product achievements, he launched Tagamet® in the US at SmithKline, positioned Capoten® for heart failure, completed the pre-launch of Pravachol® at Squibb, and led the funding of Velcade® development at ProScript. Mr. Bagley also served on a senior advisory committee at MD Anderson Cancer Center, was a member of the board of the Fox Chase Cancer Center, and a founding director of BIO (the Biotechnology Industry Organization). Mr. Bagley obtained his M.A. in Teaching in Biological Sciences from the Harvard School of Education and his B.S. in Biology from Trinity College.
John Amedio, Ph.D.
Acting Chief Manufacturing Officer
Dr. John Amedio serves as Chief Manufacturing Officer at Samus Therapeutics. Dr. Amedio’s experience spans more than 25 years in the pharmaceutical industry. Prior to joining Samus in 2016, Dr. Amedio most recently served as Principal at Amedio CMC Consulting, where he specialized in providing strategy for the technical and regulatory CMC development processes for biotechnology and pharmaceutical companies working to bring drugs through to market. Prior to consulting, Dr. Amedio served in several manufacturing guidance leadership roles, including positions at Seaside Therapeutics, ZIOPHARM Oncology, EPIX Pharmaceuticals and Sandoz Research Institute. Dr. Amedio obtained his Ph.D. in Organic Chemistry from the University of Delaware and earned his B.S. in Chemistry from Manhattan College. Dr. Amedio completed his post-doctoral research in Natural Product Synthesis and Organic Chemistry at Oregon State University.
Barbara Wallner, Ph.D.
Chief Scientific Officer
Dr. Barbara Wallner joined Samus Therapeutics in January 2017. Dr. Wallner has over 30 years of experience in biotechnology companies with domestic and international operations. Her expertise ranges from establishing corporate strategies to leading company operations in research and development, business development and intellectual property management, establishing and leading corporate partnerships, coordinating multi-company project teams and academic collaborations. Dr. Wallner obtained her B.S. and Ph.D. in Biochemistry from the University of Illinois, and spent her postdoctoral fellowship in Molecular Biology at Harvard University. She started her biotechnology career as one of the first scientists at Biogen, Inc, where she invented Amevive, which obtained market approval for psoriasis. She subsequently served as Vice President of Research and Chair of Scientific Advisory Board at Immulogic, Inc. She co-founded Point Therapeutics, Inc., a biotechnology company where she served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chairman of the Scientific Advisory Board. Point Therapeutics went public and was later acquired by DARA Biosciences. Dr. Wallner then took the position of Chief Scientific Officer and Senior Vice President of Research at BioTransplant, Inc. and subsequently joined ZIOPHARM Oncology as Chief Technology Officer and Senior Vice President of Technology Operations. Dr. Wallner’s areas of scientific expertise include biochemistry, molecular biology, cell biology, immunology, and small molecule and peptide chemistry. During her career Dr. Wallner authored 43 US issued patents and more than 120 patent applications published and issued world-wide.
Hagop Youssoufian, M.Sc, M.D.
Acting Chief Medical Officer
Dr. Hagop Youssoufian is a physician-scientist with >25 years of experience in drug development working with pharmaceutical companies from seed-stage ventures to multi-national biotech and pharmaceutical corporations. He received a B.S. in biology from Boston College (magna cum laude) and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins, Harvard and MIT. After a successful academic career as a clinician, teacher and an NIH-funded investigator, he held increasingly senior roles in clinical and translational science at Bristol-Myers Squibb (head of Experimental Medicine), Sanofi Aventis (Distinguished Scientist), ImClone (CMO), Ziopharm Oncology (President of R&D and CMO), Progenics (EVP of R&D), and BIND (CMO). He supported or led the development and approval of Sprycel, Taxotere, Elitek, Erbitux, Cyramza, Portrazza, Lartruvo, Relistor and Copiktra and played key roles in the acquisition of ImClone by Eli Lilly and BIND by Pfizer. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of over 100 publications.
Chief Financial Officer
Tyler Cook brings to Samus Therapeutics over 17 years of experience in the areas of corporate and private investment finance, financial controls and operations. Mr. Cook joined Samus as Vice President of Finance and Administration in September 2017. Mr. Cook joined Samus from Allied Universal, where he served as a general manager with responsibility for business operations throughout multiple regions in North Carolina for the nation’s largest security services company. Previously, he served as Senior Vice President, Finance, Administration and IT Systems at Ziopharm Oncology. Prior to joining Ziopharm, he served as an analyst at KLS Professional Advisors, LLC and as a private client investment services representative at Sanford C. Bernstein. Mr. Cook obtained his B.S. in Management from the University of Massachusetts.
Greg Hileman, Ph.D.
Chief Regulatory & Quality Officer
Dr. Hileman has more than 25 years of pharmaceutical regulatory affairs experience, specializing in strategic global regulatory affairs, Food and Drug Administration (FDA) and European Medicines Agency (EMA) meeting management, project team leadership, and pharmaceutical sciences. His areas of therapeutic experience include neurology (sleep disturbances, pain, Alzheimer disease, migraine, epilepsy, seizure disorders, stroke), psychiatry (depression, anxiety, schizophrenia), drug addiction, antibiotics, oncology, reproductive health, osteoarthritis, and osteoporosis. Before joining Cato Research, Dr. Hileman served 19 years at GlaxoSmithKline, most recently as executive director of Global Discovery Regulatory Affairs. At Cato Research, Dr. Hileman is a senior director of regulatory affairs and a principal regulatory scientist in the Regulatory Strategy department, working with project teams guiding biologics, drugs, and medical devices through the regulatory process. He has authored multiple Investigational New Drug applications (INDs), Clinical Trial Applications, New Drug Applications (NDAs), Biologics License Applications, orphan drug designations, fast track designations, and breakthrough therapy applications in traditional and common technical document format, as well as final study reports, clinical protocols, annual reports (Development Safety Update Reports), United States (U.S.) pediatric study plans, European Union pediatric investigational plans, gap analyses, and other sponsor-specific reports, including submissions to European Union regulatory agencies. Dr. Hileman earned a B.S. in pharmacy from the St. Louis College of Pharmacy and a Ph.D. in pharmaceutical sciences and physical chemistry from the University of Missouri-Kansas City.
Principal Patent Strategist
Ms. Channing brings over 30 years of experience providing consulting services to various biotechnology, pharmaceutical, drug delivery, device and diagnostic companies in the field of intellectual property law and related legal disciplines including promulgation of an intellectual property strategy with emphasis on patent lifecycle management. Ms. Channing has served in senior legal roles at Proscript and ImmuLogic Pharmaceutical, where she was Vice President and General Counsel. Ms. Channing began her career at Kenway & Jenney, and later became a patent attorney at W.R. Grace & Co. Ms. Channing received her A.B. in Biology and Political Science from Brown University and her J.D. from Boston University School of Law. She also served as an adjunct Professor at Suffolk University Law School.